Skip to main content
Clinical Trials/NCT05200234
NCT05200234
Recruiting
Not Applicable

Improving Cerebral Blood Flow and Cognitive Function in Patients With Asymptomatic Intracranial / Carotid Stenosis With Nattokinase (ICC-PACS): a Randomized Controlled Trial

Second Affiliated Hospital, School of Medicine, Zhejiang University1 site in 1 country100 target enrollmentJanuary 13, 2022

Overview

Phase
Not Applicable
Intervention
Placebo
Conditions
Cerebral Blood Flow
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment
100
Locations
1
Primary Endpoint
Changes in the scores of Montreal Cognitive Assessment
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

A randomized controlled trial will be conducted. Patients with asymptomatic intracranial / carotid stenosis will be randomized into two arms (1:1): an intervention arm and a control arm. Patients in the intervention arm will be treated with standard medical treatment combined with Natto Products V, whereas Patient in the control arm will be treated with only standard medical treatment . And the impact of Natto Products V on improving cerebral blood flow and cognitive function in patients with asymptomatic intracranial / carotid stenosis will be assessed by neuropsychological scale and multimode magnetic resonance imaging.

Registry
clinicaltrials.gov
Start Date
January 13, 2022
End Date
December 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged ≥ 40 years
  • ≥ 50% stenosis in unilateral intracranial / carotid artery
  • Written informed consent available

Exclusion Criteria

  • Previous history of major head trauma and any intracranial surgery
  • Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions
  • Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement
  • severe loss of vision, hearing, or communicative ability
  • plan to be treated with surgery

Arms & Interventions

Control group

Placebo + Standard medical treatment

Intervention: Placebo

Intervention group

Nattokinase + standard medical treatment

Intervention: Nattokinase

Outcomes

Primary Outcomes

Changes in the scores of Montreal Cognitive Assessment

Time Frame: 6 months

Total score of 30

Secondary Outcomes

  • Changes in metabonomics(6 months)
  • Changes in the scores of Hopkins Verbal Learning Test(6 months)
  • Changes in the scores of Animal Fluency Test(6 months)
  • Changes in the scores of Olfactory stick test(6 months)
  • Changes in the scores of clock drawing test(6 months)
  • Changes in the scores of Mini-mental State Examination(6 months)
  • Changes in cerebral blood flow in the territory of the culprit artery(6 months)
  • Changes in cerebral glymphatic function(6 months)
  • Changes in the scores of Colour Trail Test(6 months)
  • Incidence of stroke event including ischemic and hemorrhagic stroke(6 months)

Study Sites (1)

Loading locations...

Similar Trials